Ramucirumab biosimilar - Shanghai Henlius Biotech
Alternative Names: HLX-12Latest Information Update: 20 Jun 2023
At a glance
- Originator Shanghai Henlius Biotech
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Colorectal cancer; Gastric cancer; Non-small cell lung cancer
Most Recent Events
- 20 Jun 2023 Discontinued - Phase-I for Colorectal cancer (In volunteers) in China (IV) (before June 2023) (Shanghai Henlius Biotech Pipeline, June 2023)
- 20 Jun 2023 Discontinued - Phase-I for Gastric cancer (In volunteers) in China (IV) (before June 2023) (Shanghai Henlius Biotech Pipeline, June 2023)
- 20 Jun 2023 Discontinued - Phase-I for Non-small cell lung cancer (In volunteers) in China (IV) (before June 2023) (Shanghai Henlius Biotech Pipeline, June 2023)